“Antibiotic resistance is one of the biggest threats to global heath, food security and development today”
Each year in the U.S., more than 2 million people contract antibiotic resistant infections resulting in greater than 23,000 deaths and the rate of resistance is increasing. – World Health Organization
Cobio Diagnostics
Cobio Diagnostics is a life sciences biotechnology company dedicated to the development and commercialization of rapid, next-generation, phage-amplified diagnostics for bacterial ID and phenotypic detection of antibiotic resistance.
Antimicrobial resistance is one of the biggest public health challenges facing the world today and Cobio Diagnostics is developing a critical tool to address this challenge. The ineffective practice of administering broad-spectrum antibiotics while waiting for test results can be replaced with effective treatment that provides only the needed antibiotic at the needed dose.
Why Cobio?
Cobio’s new phage-based immunoassay “PhAAST-MIC” for Phage-Amplified Antimicrobial Susceptibility Test and Minimum Inhibitory Concentration, allows direct-from-specimen determination of species-specific bacterial identification, antimicrobial susceptibility, and quantitative minimum inhibitory concentration in less than 5 hours.
The method is designed with simplicity in mind and basic aseptic technique and pipetting skills are all that is required of the technician. A conventional plate reader and consumables are the only required equipment.
The method is scalable, applicable to low-tech settings, and is differentiated from current diagnostic standards by its reduced time to results, reduction of costs, and wide applicability to many pathogens.